Moderna, Inc. has announced a major expansion of its U.S. manufacturing network with plans to bring Drug Product (DP) manufacturing to its Moderna Technology Center (MTC) in Norwood, Massachusetts. The move will allow the company to operate full, end-to-end manufacturing of its mRNA medicines within the United States, marking a significant milestone in its long-term strategy to strengthen domestic capabilities.
According to Moderna, the addition of DP manufacturing at MTC completes the full production cycle—from mRNA synthesis to final drug product packaging—on a single U.S. campus. This integration is positioned to enhance supply reliability, accelerate production timelines, and support both commercial and clinical programs across Moderna’s expanding pipeline.
CEO Stéphane Bancel emphasized the importance of this development in reinforcing the company’s commitment to U.S.-based innovation and manufacturing. “By onshoring Drug Product manufacturing to our campus in Norwood, Massachusetts, we have completed the full manufacturing loop under one roof in the U.S.,” Bancel said. “As an American company committed to building and producing in America, we are proud to strengthen our domestic footprint while bringing meaningful new jobs to the community.”
The expansion aligns with Moderna’s broader investment strategy aimed at building a robust domestic infrastructure capable of supporting its suite of mRNA therapies. The company’s mRNA platform gained global prominence during the COVID-19 pandemic through its collaboration with the U.S. government under Operation Warp Speed. Since then, Moderna has continued to advance mRNA applications across infectious diseases, oncology, rare diseases, and autoimmune disorders. Strengthening U.S. manufacturing, executives say, is essential for supporting future commercial launches and ensuring reliable access to critical medicines.
Construction of the new DP manufacturing facilities at the Norwood campus has already begun. Moderna expects the build-out to be completed by the first half of 2027. Once operational, the facility is anticipated to create new high-skilled jobs and provide additional capacity to support both U.S. and global supply needs.
The company noted that consolidating manufacturing under one roof will also improve operational efficiency and agility—key advantages as Moderna prepares for potential future pandemics or surges in demand for mRNA-based products. As its clinical pipeline broadens, internal control of end-to-end manufacturing is expected to provide greater flexibility and resilience.
Moderna’s investment in Norwood reflects a growing trend among biopharmaceutical companies to localize production and reduce dependence on international supply chains. With this expansion, Moderna aims to strengthen its competitive position in the rapidly evolving mRNA landscape while contributing to U.S. biomanufacturing leadership.